Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany

Georg Evers, Franziska Glanemann, Maximilian Webendörfer, Marcel Wiesweg, Dennis Görlich, Daniel C. Christoph, Petra Hoffknecht, Heiner Zimmermann, Fabian Acker, Martin Sebastian, Andrea Kerkhoff, Michael Mohr, Georg Lenz, Anna-Carina Hund, Tobias R. Overbeck, Nikolaj Frost, Martin Faehling, Wolfgang M. Brückl, Cornelia Kropf-Sanchen, Wolfgang Schütte, Frank Griesinger, Lea E. Reitnauer, Annalen Bleckmann

Therapeutic Advances in Medical Oncology

Published online on July 23, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Despite recent advances in the treatment of locally advanced non-small cell lung cancer (NSCLC), most patients relapse after definitive chemoradiotherapy followed by durvalumab consolidation. Due to limited evidence on post-relapse management, ...